ACUS: AI 评分 61/100 — AI 分析 (4月 2026)

Acusphere, Inc. is a specialty pharmaceutical company focused on developing and commercializing cardiovascular drugs. Its primary product, Imagify, is used for evaluating myocardial perfusion and detecting coronary artery disease.

Key Facts: AI Score: 61/100 Sector: Healthcare

公司概况

概要：

Acusphere, Inc., a specialty pharmaceutical company, focuses on cardiovascular drug development and commercialization. Its key product, Imagify, aids in myocardial perfusion evaluation and coronary artery disease detection. Operating in the specialty and generic drug manufacturing sector, Acusphere aims to address unmet needs in cardiovascular diagnostics, though it faces challenges common to small-cap pharmaceutical firms.

ACUS是做什么的？

Acusphere, Inc., founded in 1993 and based in Watertown, Massachusetts, operates as a specialty pharmaceutical company focused on developing and commercializing cardiovascular drugs. Originally named Polymers For Medicine, Inc., the company changed its name to Acusphere, Inc. in March 2004. Its primary product is Imagify (perflubutane polymer microspheres), an injectable suspension used to evaluate myocardial perfusion and detect coronary artery disease. Imagify is designed to enhance the visualization of the heart during echocardiography, aiding in the diagnosis of heart conditions. The company's focus is on addressing unmet needs in cardiovascular diagnostics, a critical area given the prevalence of heart disease globally. Acusphere's business model centers on the development, manufacturing, and marketing of specialized pharmaceutical products for cardiovascular applications. The company targets healthcare professionals and medical facilities specializing in cardiology and diagnostic imaging. Acusphere operates primarily in the United States, with potential for future expansion into international markets. The company faces competition from larger pharmaceutical companies with broader product portfolios and greater resources, as well as smaller companies focused on similar diagnostic technologies.

ACUS的投资论点是什么？

Acusphere, Inc. presents a high-risk, high-reward investment profile due to its focus on a single product, Imagify, in the cardiovascular diagnostics market. The company's financial performance, characterized by a negative profit margin of -2014.6%, indicates significant challenges in achieving profitability. Key value drivers include the potential for increased adoption of Imagify in clinical practice and the expansion of its applications to other cardiovascular conditions. Ongoing catalysts include potential partnerships or acquisitions that could provide financial stability and market access. However, potential risks include regulatory hurdles, competition from established players, and the need for additional funding to support ongoing operations and research. Investors should carefully consider the company's financial position and the competitive landscape before making investment decisions.

ACUS在哪个行业运营？

Acusphere, Inc. operates within the specialty pharmaceutical industry, which is characterized by high research and development costs, stringent regulatory requirements, and intense competition. The cardiovascular diagnostics market is driven by the increasing prevalence of heart disease and the growing demand for non-invasive diagnostic procedures. Acusphere's Imagify competes with other imaging agents and diagnostic technologies. The industry is also influenced by technological advancements in medical imaging and the shift towards personalized medicine. The global cardiovascular diagnostic market is projected to reach billions of dollars in the coming years, presenting both opportunities and challenges for companies like Acusphere.

Drug Manufacturers - Specialty & Generic

Healthcare

ACUS有哪些增长机遇？

Expansion of Imagify's Applications: Acusphere has the opportunity to expand the clinical applications of Imagify beyond its current use in myocardial perfusion evaluation. Research into using Imagify for detecting other cardiovascular conditions, such as pulmonary hypertension or valvular heart disease, could open new markets. The market for cardiovascular imaging is projected to grow, driven by the increasing prevalence of heart disease. Timeline: 2-3 years for initial research and clinical trials, followed by regulatory approval.
Strategic Partnerships: Forming strategic partnerships with larger pharmaceutical companies or medical device manufacturers could provide Acusphere with access to broader distribution networks and increased financial resources. Collaborations could also facilitate the development of new formulations or delivery methods for Imagify. The pharmaceutical industry is characterized by frequent collaborations and acquisitions. Timeline: 1-2 years for identifying and establishing partnerships.
Geographic Expansion: Acusphere could pursue geographic expansion by seeking regulatory approval for Imagify in international markets, such as Europe and Asia. These markets represent significant growth opportunities due to their large populations and increasing healthcare spending. The global market for cardiovascular diagnostics is expanding rapidly. Timeline: 2-4 years for regulatory approval and market entry.
Development of New Cardiovascular Drugs: Acusphere could leverage its expertise in cardiovascular drug development to create new products that address unmet needs in the market. This could involve developing new formulations of existing drugs or creating entirely new therapeutic agents. The cardiovascular drug market is characterized by continuous innovation. Timeline: 5-7 years for drug development and regulatory approval.
Adoption of AI-Driven Diagnostics: Integrating artificial intelligence (AI) into the diagnostic process using Imagify could improve the accuracy and efficiency of cardiovascular assessments. AI algorithms could be used to analyze images and identify subtle abnormalities that might be missed by human observers. The market for AI in healthcare is growing rapidly. Timeline: 1-3 years for developing and implementing AI-driven diagnostic tools.

Acusphere, Inc. operates in the specialty pharmaceutical sector, focusing on cardiovascular drugs.
The company's primary product is Imagify (perflubutane polymer microspheres), used for myocardial perfusion evaluation and coronary artery disease detection.
Acusphere's gross margin is 100.0%, indicating efficient cost management in production, but its profit margin is -2014.6%.
The company's beta is -0.52, suggesting a negative correlation with the overall market.
Acusphere does not currently offer a dividend.

ACUS提供哪些产品和服务？

Develops specialty pharmaceutical products.
Focuses on cardiovascular drugs.
Commercializes cardiovascular drugs.
Offers Imagify (perflubutane polymer microspheres).
Imagify is used to evaluate myocardial perfusion.
Imagify helps detect coronary artery disease.
Provides Imagify as an injectable suspension.

ACUS如何赚钱？

Develops and manufactures Imagify.
Markets and sells Imagify to healthcare professionals and medical facilities.
Generates revenue through sales of Imagify.

Hospitals
Cardiologists
Diagnostic imaging centers

Specialized product (Imagify) in a niche market.
Proprietary formulation of perflubutane polymer microspheres.
Established relationships with cardiologists and medical facilities.

什么因素可能推动ACUS股价上涨？

Upcoming: Potential partnerships with larger pharmaceutical companies for expanded distribution.
Upcoming: Regulatory approval for Imagify in international markets.
Ongoing: Research and development efforts to expand the clinical applications of Imagify.
Ongoing: Efforts to secure additional funding to support operations and research.

ACUS的主要风险是什么？

Potential: Competition from established pharmaceutical companies with greater resources.
Potential: Regulatory hurdles and approval processes for new drugs and indications.
Potential: Product obsolescence due to technological advancements in cardiovascular diagnostics.
Ongoing: Need for additional funding to support ongoing operations and research.
Ongoing: Limited product portfolio and reliance on a single product for revenue generation.

ACUS的核心优势是什么？

Specialized product (Imagify) for cardiovascular diagnostics.
Proprietary formulation of perflubutane polymer microspheres.
Focus on a specific therapeutic area (cardiovascular disease).
Gross margin of 100.0%

ACUS的劣势是什么？

Limited product portfolio (primarily Imagify).
Negative profit margin (-2014.6%).
Small market capitalization.
Reliance on a single product for revenue generation.

ACUS有哪些机遇？

Expansion of Imagify's applications to other cardiovascular conditions.
Geographic expansion into international markets.
Strategic partnerships with larger pharmaceutical companies.
Development of new cardiovascular drugs.

ACUS面临哪些威胁？

Competition from established pharmaceutical companies.
Regulatory hurdles and approval processes.
Potential for product obsolescence due to technological advancements.
Need for additional funding to support ongoing operations and research.

Key Metrics

MoonshotScore: 61/100

Company Profile

CEO: William I. Ramage D.Phil
Headquarters: Watertown, US
Founded: 2003

AI Insight

AI analysis pending for ACUS

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Acusphere, Inc. do?

Acusphere, Inc. is a specialty pharmaceutical company that develops and commercializes cardiovascular drugs. Its primary product, Imagify (perflubutane polymer microspheres), is an injectable suspension used to evaluate myocardial perfusion and detect coronary artery disease. The company focuses on providing diagnostic solutions for cardiovascular conditions, targeting healthcare professionals and medical facilities specializing in cardiology and diagnostic imaging. Acusphere operates primarily in the United States, with potential for future expansion into international markets, aiming to address unmet needs in cardiovascular diagnostics.

What do analysts say about ACUS stock?

AI analysis is currently pending for ACUS stock. Without analyst ratings or price targets, it's challenging to provide a consensus view. However, key valuation metrics to consider include the company's market capitalization, revenue growth (if any), and profitability (or lack thereof). Investors should also assess the company's growth prospects, competitive landscape, and potential risks before making investment decisions. Further analysis will be available upon completion of the AI assessment.

What are the main risks for ACUS?

Acusphere, Inc. faces several key risks, including its limited product portfolio and reliance on a single product, Imagify, for revenue generation. The company also faces competition from larger pharmaceutical companies with greater resources and established market presence. Regulatory hurdles and approval processes for new drugs and indications pose another significant risk. Additionally, the company's negative profit margin and need for additional funding create financial challenges. Investors should carefully consider these risks before investing in ACUS.